Literature DB >> 22285837

Hyperoxidized peroxiredoxins in peripheral blood mononuclear cells of asthma patients is associated with asthma severity.

Hyouk-Soo Kwon1, Yun-Jeong Bae, Keun-Ai Moon, Yoon Su Lee, Taehoon Lee, Ki-Young Lee, Tae-Bum Kim, Chan-Sun Park, Hee-Bom Moon, You Sook Cho.   

Abstract

AIMS: Oxidative stress is involved in the pathogenesis of asthma, and peroxiredoxins (PRDX) may be critical in controlling intracellular oxidative stress. The aim of this study was to evaluate expressions of PRDX and their hyperoxidized forms in asthmatic individuals. MAIN
METHODS: The levels of expression of PRDX1, PRDX2, PRDX3, and PRDX6 and their hyperoxidized forms (PRDX-SO(3)) were measured in PBMCs from asthma patients and control subjects. In addition, cells from these subjects were treated with hydrogen peroxide (H(2)O(2)) and their intracellular concentrations of reactive oxygen species (ROS) were measured. KEY
FINDINGS: The ratios of hyperoxidized to total PRDX (PRDX-SO(3/)PRDX) in PBMCs were significantly higher in asthma patients than in normal subjects and were correlated with disease severity, with the highest ratio seen in patients with severe asthma. Furthermore, H(2)O(2) treatment of PBMCs, particularly lymphocytes, increased intracellular ROS concentrations with greater and more persistent increases observed in cells from asthmatic than from control subjects. SIGNIFICANCE: Hyperoxidation of PRDX may serve as a biomarker of asthma severity and may predict enhanced susceptibility to oxidative stress load in PBMCs of asthmatics.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285837     DOI: 10.1016/j.lfs.2012.01.003

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

Review 1.  Mitochondrial biology in airway pathogenesis and the role of NRF2.

Authors:  Hye-Youn Cho; Steven R Kleeberger
Journal:  Arch Pharm Res       Date:  2019-09-04       Impact factor: 4.946

2.  Peroxidatic cysteine residue of peroxiredoxin 2 separated from human red blood cells treated by tert-butyl hydroperoxide is hyperoxidized into sulfinic and sulfonic acids.

Authors:  Yo-Ichi Ishida; Mariko Aki; Sohta Fujiwara; Masami Nagahama; Yuki Ogasawara
Journal:  Hum Cell       Date:  2017-04-22       Impact factor: 4.174

3.  PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.

Authors:  Hyung-Mun Yun; Dong Young Choi; Ki Wan Oh; Jin Tae Hong
Journal:  Mol Neurobiol       Date:  2014-09-06       Impact factor: 5.590

4.  Susceptibility to COPD: differential proteomic profiling after acute smoking.

Authors:  Lorenza Franciosi; Dirkje S Postma; Maarten van den Berge; Natalia Govorukhina; Peter L Horvatovich; Fabrizia Fusetti; Bert Poolman; Monique E Lodewijk; Wim Timens; Rainer Bischoff; Nick H T ten Hacken
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

5.  Plasma proteins as potential targets of abnormal Savda syndrome in asthma patients treated with unique Uighur prescription.

Authors:  Canhua Zhang; Abulizi Abudula; Maliyegu Awuti; Huiwu Wang; Xiaimuxikamaier Aihemaiti; Turghun Tusung; Xierzhatijiang Sulaiman; Halmurat Upur
Journal:  Exp Ther Med       Date:  2017-05-23       Impact factor: 2.447

6.  Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway.

Authors:  Yanxia Jin; Qian Yang; Li Liang; Lu Ding; Yuxing Liang; Dongdong Zhang; Balu Wu; Tian Yang; Hailing Liu; Tingting Huang; Hui Shen; Honglei Tu; Yunbao Pan; Yongchang Wei; Yi Yang; Fuling Zhou
Journal:  J Exp Clin Cancer Res       Date:  2018-11-19

7.  Oxidative Stress Modulates the Expression Pattern of Peroxiredoxin-6 in Peripheral Blood Mononuclear Cells of Asthmatic Patients and Bronchial Epithelial Cells.

Authors:  Hyun Jae Shim; So Young Park; Hyouk Soo Kwon; Woo Jung Song; Tae Bum Kim; Keun Ai Moon; Jun Pyo Choi; Sin Jeong Kim; You Sook Cho
Journal:  Allergy Asthma Immunol Res       Date:  2020-05       Impact factor: 5.764

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.